For sales

📢Highlights from the Week of 28th July, 2025 – 4th August, 2025   in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of 28th July, 2025 - 4th August, 2025 VYUHPHARMA (FDA, Approval) PTC THERAPEUTICS FDA approves PTC Therapeutics' SEPHIENCE (sepiapterin) for the treatment of phenylketonuria (PKU) in children and adults (FDA, Approval) NOVARTIS FDA approves Novartis' twice-yearly LEQVIO (inclisiran) for new first-line monotherapy use in adults with high cholesterol (FDA, Approval) novo nordisk Novo Nordisk's ALHEMO receives expanded FDA approval as a once-daily subcutaneous prophylactic for hemophilia A or B without inhibitors Apellis (FDA, Approval) FDA approves Apellis' EMPAVELI (pegcetacoplan) as the first C3G and primary IC-MPGN treatment for patients 12 and older, demonstrating significant efficacy Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.